Patents

Recent Articles

•  

  13/08/2024

  Europe

  Antibody Appeals Uncovered

  Since the first approval of Muromonab-CD3 in 1986, antibodies have become progressively more common, frequently reaching a ‘blockbuster’ status. According to statistics provided by Statista in March, 5 out of 10 top-selling drugs were antibodies in 2023. Therefore, patents related to antibodies are now of considerable interest and significance to the pharmaceutical industry. They provide protection for commercially important inventions, spur further investment, and allow patients to benefit from these therapeutics. Our report provides a high-level analysis of the Board of Appeal decisions...

  Read more
•  

  19/07/2024

  Europe

  A healthy balance between novelty and sufficiency for a claimed therapeutic use in view of a clinical trial disclosure in healthy volunteers (T 209/22)

  The question of novelty and sufficiency of second medical use claims in light of clinical trial prior art has been addressed by the EPO Boards of Appeal on a number of occasions. In recent decision T 209/22, the Appeal Board considers the impact of a disclosure relating to a clinical trial in healthy volunteers. The Appeal Board also comments on the different standards that apply for novelty and sufficiency of disclosure. The decision highlights that an attack based on novelty-sufficiency squeeze may not always be effective.BackgroundThe present decision relates to European patent 2506844 which...

  Read more
•  

  13/06/2024

  Europe

  What’s in a name? The use of a product code in a clinical trial protocol fails to circumvent clinical trial prior art (T 1255/21)

  The use of product or sponsor codes in clinical trial related documents is common practice in the pharmaceutical space. However, such codes may not always be sufficient to disregard a publication as relevant prior art against patent claims.In recent decision T 1255/21, the EPO Board of Appeal finds that the use of a product code or sponsor code for a compound or composition in a clinical trial protocol does not affect the status of the protocol as prior art if the skilled person would have been able to identify the compound or composition based on the description of the components of the product...

  Read more
•  

  04/06/2024

  China

  China’s market regulator announces top ten IP infringements of 2023

  On 10 May 2024, China’s State Administration for Market Regulation (SAMR) announced the top ten typical cases of intellectual property (IP) enforcement for 2023, which encompassed a range of illegal activities, including the production and sale of counterfeit branded automobile glass, the illicit manufacture and sale of fake cosmetics, the sale of tea infringing upon the “中茶” tea brand registered trademark, the infringement of “DENSO” and “TOYOTA” trademarks, the sale of goods bearing the counterfeit "FION" trademark, and the sale of counterfeit...

  Read more
•  

  16/05/2024

  Europe

  A broader interpretation of "substance or composition" - good news for patentees at the EPO?

  A recent decision from the EPO Boards of Appeal (T 1252/20) potentially paves the way for more diverse products to be patentable in Europe using the medical use claim format.The background:Article 53(c) of the European Patent Convention (EPC) excludes methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body from patentability. However, this does not apply to products, in particular substances or compositions, for use in any of these methods.Furthermore, Articles 54(4) and (5) EPC provide that a claim to a known substance...

  Read more
•  

  15/04/2024

  APAC region

  Top IP developments and predictions across Asia-Pacific

  We look back at the top developments over the last 12 months in Intellectual Property (IP) and we look to the future by offering our top predictions for the coming year for businesses operating across Asia Pacific (APAC) with an emphasis on mainland China, Hong Kong and Singapore.Over the last year, we have seen the continuous and rapid development of IP systems in APAC jurisdictions, including the reciprocal enforcement of IP judgments between Hong Kong and mainland China and innovative Chinese court decisions on FRAND rates and the copyright of AI-generated images.  Over the coming year,...

  Read more